EXPLORE MORE CATEGORIES
- Home
- ยป
- Our Products
- »
- Pharmaceutical Solution
Pharmaceutical Solution
Leading Exporter of enzalutamide bdenza-os 32mg oral solution from Surat.
Enzalutamide Bdenza-OS 32mg Oral Solution
Product Price: Rs 24,500 / BoxGet Best Price
Minimum Order Quantity: 10 Box
Product Brochure
Product Details:
| Strength | 32 mg/ml |
| Packaging Size | 150 ml in 1 Bottle |
| Composition | Enzalutamide 32mg/ml |
| Brand Name | Bdenza OS Oral Solution |
| Manufacturer | BDR Pharmaceuticals Internationals Pvt |
| Treatment | Prostate Cancer |
Overview
Bdenza-OS, containing enzalutamide, is an oral medication used primarily for the treatment of prostate cancer. It is specifically indicated for patients with metastatic castration-resistant prostate cancer (mCRPC) and has been shown to improve overall survival.
- Metastatic Castration-Resistant Prostate Cancer (mCRPC): Used in adult men whose cancer has progressed despite hormone therapy.
- Non-Metastatic Castration-Resistant Prostate Cancer: Approved for patients at high risk of developing metastatic disease.
Enzalutamide works by:
- Androgen Receptor Inhibition: It blocks the androgen receptors, preventing testosterone and other androgens from promoting the growth of prostate cancer cells.
- Inhibiting Androgen Receptor Nuclear Translocation: It prevents the receptor from moving into the nucleus, where it would activate genes that drive cancer growth.
- Blocking Androgen Production: It reduces the ability of prostate cancer cells to utilize androgens.
- Dosage: The usual recommended dose is 160 mg (administered as 5 mL of the oral solution) once daily. Your healthcare provider may adjust the dosage based on individual needs.
- Administration: Can be taken with or without food. Shake the oral solution well before use and measure the dose carefully using an appropriate measuring device.
Common side effects may include:
- Fatigue
- Hot flashes
- Diarrhea
- Nausea
- Hypertension
- Seizures: Enzalutamide may increase the risk of seizures; caution is advised in patients with a history of seizures or other predisposing factors.
- Adrenal Insufficiency: Monitor for signs and symptoms, particularly in patients receiving concomitant corticosteroids.
- Liver Function: Regular liver function tests are recommended, as enzalutamide can affect liver enzymes.
- Hypersensitivity: Known allergies to enzalutamide or any components of the formulation.
- Enzalutamide may interact with other medications, especially those that affect liver enzymes (CYP2C8 and CYP3A4). Always inform your healthcare provider of all medications and supplements being taken.
- Store Bdenza-OS at room temperature, away from light and moisture. Keep out of reach of children.
- Educate patients about the importance of adhering to the prescribed dosing schedule and the need for regular follow-up appointments.
- Advise them to report any unusual symptoms, such as seizures or severe side effects.
- Discuss the potential for drug interactions and the importance of informing healthcare providers about all medications they are taking.
Enzalutamide (Bdenza-OS 32 mg Oral Solution) is an essential treatment for managing advanced prostate cancer. Its mechanism of action helps control disease progression, improving patient outcomes. Proper monitoring and patient education are crucial for the safe and effective use of this medication. Always consult a healthcare provider for personalized advice and guidance.
4o miniYes! I am InterestedRequest A Callback